Loading stock data…
$41.52-0.41 (-0.98%)
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Enliven Therapeutics, Inc. in the Healthcare sector is trading at $41.52 with a market capitalization of $3.7B. Wall Street consensus targets $74.42 (12 analysts), implying a +79.2% move over the next 12 months. The stock is currently 33% below its 52-week high of $62.32, remaining 1.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$37.21M↓ | -$27.82M↑ | -$34.28M↓ | -$25.10M↑ | -$28.58M |
| Net Income | -$32.48M↓ | -$23.63M↑ | -$29.67M↓ | -$20.15M↑ | -$25.34M |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor whi...